'I used to be constantly horny - my partner was heartbroken after sudden change'
When it came to intimacy in the bedroom, Leanne Jones and her partner Adam never encountered any issues. In fact, the 42-year-old described herself as being "very highly sex driven", but then something switched.
"I went from being very highly sex driven to feeling like Grandpa Joe from Willy Wonka," Leanne told The Sun. Unaware of what had suddenly changed, the mum-of-two from South Wales said that at first her partner, Adam, "took it personally" and thought she didn't love him anymore.
It became a confusing time for Leanne as she struggled to get aroused, and when they had sex, she was unable to climax as usual. It comes after the NHS warns mouth symptom could be life-shortening disease.
"I was left heartbroken. No matter how hard I tried, I couldn't get back my once horny self", the former legal secretary shared.
Just a few years prior, in March 2020, Leanne was diagnosed with Multiple Sclerosis, also known as MS, which is a lifelong condition that affects the brain and nerves. But she never thought this would start to impact her sex life.
"When it impacts your enjoyment in the bedroom and intimacy with your partner, it is very difficult," she revealed. Her relationship with Adam began in 2023, and they had enjoyed an intimate relationship before her GP confirmed that her MS was likely the cause of the lack of sex drive.
Leanne explained that because of the nerve damage to the brain and spine, "the signals needed for arousal, sensation, and orgasm are no longer there", which "creates a disconnect". Taking to TikTok for support, she found that she wasn't the only one with MS to experience a drop in her sex life, and said some saw their partner leave them due to not knowing MS could impact intimacy in the bedroom.
Knowing her MS had caused the drop in sex drive, Leanne was able to talk to her partner about it, who understands the problem is not him, but her brain. They've since been able to work together to know when the best time to be intimate together is and have sex "a few times a week".
In addition to her sex life, MS impacts Leanne every day as she experiences issues with speech, vision, and mobility, along with extreme fatigue, restless legs, and absence seizures. These can worryingly cause her to "blank out" or stare into space.
Due to her MS, where her symptoms come and go, Leanne was forced to take early retirement and said it impacts her mental, emotional, and physical health. She labelled MS as a "debilitating and lonely life" but said she doesn't want people to feel like it's a "prison sentence".
Prior to her diagnosis, she had experienced numbness in her right knee, which at times would completely give way. Leanne, who led an active lifestyle, also faced "crippling" fatigue, which left her unable to move from the sofa some days, and she experienced partial hearing loss.
She went to her GP and was referred for an MRI scan, which revealed her MS condition. When it came to the results, she was unable to speak to her doctor in person, as it was the start of the COVID-19 pandemic, so she was given life-changing news in a phone call.
In 2024, the mum was also diagnosed with Functional Neurological Disorder (FND), a condition that impacts how the brain receives and sends information to the rest of the body. This can cause leg and arm weakness and seizures.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
South Wales Argus
3 hours ago
- South Wales Argus
Concern over weight gain after ‘skinny jabs'
Research shows that many people regain weight after stopping treatment if they are not supported, the National Institute for Health and Care Excellence (Nice) said. The health watchdog said that people coming off the drugs should be offered 'structured advice and follow-up support' to help prevent weight gain. The guidance is for people who are offered the treatments through the NHS. An estimated 1.5 million people are taking weight loss jabs in the UK, but the vast majority are paying for them privately so will not be eligible for NHS support after they have finished their treatment. Around 240,000 people with 'greatest need' are expected to receive Mounjaro, also known as tirzepatide, through the NHS over the next three years. The new 'quality standard' from Nice says that NHS patients should be monitored for at least a year after they complete treatment, and extra support should be offered if needed. It emphasises building 'long-term behavioural habits, use self-monitoring tools, and draw on wider support – from online communities to family-led interventions and local activities'. This standard, a type of guidance for the health services in England and Wales, sets out expectations for health providers including how they should support patients. 'Successful weight management doesn't end when medication stops or when someone completes a behavioural programme,' said Professor Jonathan Benger, deputy chief executive and chief medical officer at Nice. 'We know that the transition period after treatment is crucial, and people need structured support to maintain the positive changes they've made. 'This new standard makes sure services provide that vital continuity of care, and it supports the NHS 10 Year Plan to shift from a 'sickness service' to a genuine health service focused on prevention.' Dr Rebecca Payne, chair of Nice's Quality Standards Advisory Committee, added: 'Weight management is a long-term journey, not a short-term fix. Little swaps can make tasty, healthy changes. For lots of tips and support to eat better visit: — NHS Blackpool Teaching Hospitals 💙🌈 (@BlackpoolHosp) April 12, 2025 'The evidence is clear that advice and support for maintaining weight after stopping medicines or completing behavioural interventions can help prevent weight regain and enable people to experience lasting benefits. 'We've seen excellent examples of services that already provide comprehensive discharge planning and ongoing support. 'This quality standard will help ensure all healthcare providers adopt these best practices, giving every person the best chance of maintaining their weight management success over the long term. 'This standard ensures healthcare services are equipped to provide that essential ongoing support.' Commenting, Henry Gregg, chief executive of the National Pharmacy Association, said: 'Pharmacies take their responsibilities seriously to provide full wrap around support to patients trying to achieve a healthy weight. 'We know that although medication can be effective in speeding up weight loss in some people, it is not a silver bullet and patients need to make long term lifestyle changes to make their weight loss sustainable. 'The current NHS roll out of weight loss treatment is very small, with only a handful of patients receiving it and it will continue to be the case that the vast majority of eligible patients will be seen by their pharmacy.' Professor Kamila Hawthorne, chairwoman of the Royal College of GPs, said: 'There is no one-size-fits-all approach to tackling obesity – what works for one patient will likely not work for another and, as with any medication, weight-loss drugs do not come without risk. 'It's also the case that patients will likely need support to sustain their weight loss once they stop taking the medication. As such, this is important and sensible guidance from Nice. 'As a college, we've been clear that whilst weight loss medications have significant potential benefits for patients who are struggling to lose weight, they mustn't be seen as a 'silver bullet' and ensuring access to sufficient 'wraparound' services – particularly for when patients come off their medication – will be key to optimal health outcomes.'
Leader Live
3 hours ago
- Leader Live
Concern over weight gain after ‘skinny jabs'
Research shows that many people regain weight after stopping treatment if they are not supported, the National Institute for Health and Care Excellence (Nice) said. The health watchdog said that people coming off the drugs should be offered 'structured advice and follow-up support' to help prevent weight gain. The guidance is for people who are offered the treatments through the NHS. An estimated 1.5 million people are taking weight loss jabs in the UK, but the vast majority are paying for them privately so will not be eligible for NHS support after they have finished their treatment. Around 240,000 people with 'greatest need' are expected to receive Mounjaro, also known as tirzepatide, through the NHS over the next three years. The new 'quality standard' from Nice says that NHS patients should be monitored for at least a year after they complete treatment, and extra support should be offered if needed. It emphasises building 'long-term behavioural habits, use self-monitoring tools, and draw on wider support – from online communities to family-led interventions and local activities'. This standard, a type of guidance for the health services in England and Wales, sets out expectations for health providers including how they should support patients. 'Successful weight management doesn't end when medication stops or when someone completes a behavioural programme,' said Professor Jonathan Benger, deputy chief executive and chief medical officer at Nice. 'We know that the transition period after treatment is crucial, and people need structured support to maintain the positive changes they've made. 'This new standard makes sure services provide that vital continuity of care, and it supports the NHS 10 Year Plan to shift from a 'sickness service' to a genuine health service focused on prevention.' Dr Rebecca Payne, chair of Nice's Quality Standards Advisory Committee, added: 'Weight management is a long-term journey, not a short-term fix. Little swaps can make tasty, healthy changes. For lots of tips and support to eat better visit: — NHS Blackpool Teaching Hospitals 💙🌈 (@BlackpoolHosp) April 12, 2025 'The evidence is clear that advice and support for maintaining weight after stopping medicines or completing behavioural interventions can help prevent weight regain and enable people to experience lasting benefits. 'We've seen excellent examples of services that already provide comprehensive discharge planning and ongoing support. 'This quality standard will help ensure all healthcare providers adopt these best practices, giving every person the best chance of maintaining their weight management success over the long term. 'This standard ensures healthcare services are equipped to provide that essential ongoing support.' Commenting, Henry Gregg, chief executive of the National Pharmacy Association, said: 'Pharmacies take their responsibilities seriously to provide full wrap around support to patients trying to achieve a healthy weight. 'We know that although medication can be effective in speeding up weight loss in some people, it is not a silver bullet and patients need to make long term lifestyle changes to make their weight loss sustainable. 'The current NHS roll out of weight loss treatment is very small, with only a handful of patients receiving it and it will continue to be the case that the vast majority of eligible patients will be seen by their pharmacy.' Professor Kamila Hawthorne, chairwoman of the Royal College of GPs, said: 'There is no one-size-fits-all approach to tackling obesity – what works for one patient will likely not work for another and, as with any medication, weight-loss drugs do not come without risk. 'It's also the case that patients will likely need support to sustain their weight loss once they stop taking the medication. As such, this is important and sensible guidance from Nice. 'As a college, we've been clear that whilst weight loss medications have significant potential benefits for patients who are struggling to lose weight, they mustn't be seen as a 'silver bullet' and ensuring access to sufficient 'wraparound' services – particularly for when patients come off their medication – will be key to optimal health outcomes.'
Powys County Times
3 hours ago
- Powys County Times
Concern over weight gain after ‘skinny jabs'
Health chiefs have raised concerns about people regaining weight after using Wegovy and Mounjaro, saying that patients coming off the drugs should be given support to help prevent them piling on the pounds again. Research shows that many people regain weight after stopping treatment if they are not supported, the National Institute for Health and Care Excellence (Nice) said. The health watchdog said that people coming off the drugs should be offered 'structured advice and follow-up support' to help prevent weight gain. The guidance is for people who are offered the treatments through the NHS. An estimated 1.5 million people are taking weight loss jabs in the UK, but the vast majority are paying for them privately so will not be eligible for NHS support after they have finished their treatment. Around 240,000 people with 'greatest need' are expected to receive Mounjaro, also known as tirzepatide, through the NHS over the next three years. The new 'quality standard' from Nice says that NHS patients should be monitored for at least a year after they complete treatment, and extra support should be offered if needed. It emphasises building 'long-term behavioural habits, use self-monitoring tools, and draw on wider support – from online communities to family-led interventions and local activities'. This standard, a type of guidance for the health services in England and Wales, sets out expectations for health providers including how they should support patients. 'Successful weight management doesn't end when medication stops or when someone completes a behavioural programme,' said Professor Jonathan Benger, deputy chief executive and chief medical officer at Nice. 'We know that the transition period after treatment is crucial, and people need structured support to maintain the positive changes they've made. 'This new standard makes sure services provide that vital continuity of care, and it supports the NHS 10 Year Plan to shift from a 'sickness service' to a genuine health service focused on prevention.' Dr Rebecca Payne, chair of Nice's Quality Standards Advisory Committee, added: 'Weight management is a long-term journey, not a short-term fix. Little swaps can make tasty, healthy changes. For lots of tips and support to eat better visit: — NHS Blackpool Teaching Hospitals 💙🌈 (@BlackpoolHosp) April 12, 2025 'The evidence is clear that advice and support for maintaining weight after stopping medicines or completing behavioural interventions can help prevent weight regain and enable people to experience lasting benefits. 'We've seen excellent examples of services that already provide comprehensive discharge planning and ongoing support. 'This quality standard will help ensure all healthcare providers adopt these best practices, giving every person the best chance of maintaining their weight management success over the long term. 'This standard ensures healthcare services are equipped to provide that essential ongoing support.' Commenting, Henry Gregg, chief executive of the National Pharmacy Association, said: 'Pharmacies take their responsibilities seriously to provide full wrap around support to patients trying to achieve a healthy weight. 'We know that although medication can be effective in speeding up weight loss in some people, it is not a silver bullet and patients need to make long term lifestyle changes to make their weight loss sustainable. 'The current NHS roll out of weight loss treatment is very small, with only a handful of patients receiving it and it will continue to be the case that the vast majority of eligible patients will be seen by their pharmacy.' Professor Kamila Hawthorne, chairwoman of the Royal College of GPs, said: 'There is no one-size-fits-all approach to tackling obesity – what works for one patient will likely not work for another and, as with any medication, weight-loss drugs do not come without risk. 'It's also the case that patients will likely need support to sustain their weight loss once they stop taking the medication. As such, this is important and sensible guidance from Nice. 'As a college, we've been clear that whilst weight loss medications have significant potential benefits for patients who are struggling to lose weight, they mustn't be seen as a 'silver bullet' and ensuring access to sufficient 'wraparound' services – particularly for when patients come off their medication – will be key to optimal health outcomes.'
